{{Rsnum
|rsid=2853539
|Gene=TYMS
|Chromosome=18
|position=659829
|Orientation=plus
|GMAF=0.4031
|Gene_s=C18orf56,TYMS
|Assembly=GRCh37.p2
|GenomeBuild=37.2
|dbSNPBuild=134
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}
{{PMID Auto
|PMID=19902562
|Title=Purine biosynthetic pathway genes and methotrexate response in rheumatoid arthritis patients among north Indians
}}

{{PharmGKB
|RSID=rs2853539
|Name_s=
|Gene_s=TYMS, C18orf56
|Feature=
|Evidence=PubMed ID:19902562
|Annotation=Risk or phenotype-associated allele (s): A/A. Phenotype: Carriers of TYMS rs2853539 AA genotype [OR (95% CI) = 2.76 (1.50-5.07)] were predictors of poor response to methotrexate among rheumatoid arthritis patients Study size: 281. Study population/ethnicity: Indian metric(s): OR (95% CI) = 2.76 (1.50-5.07). Type of association: GN.
|Drugs=methotrexate
|Drug Classes=
|Diseases=Arthritis, Rheumatoid
|Curation Level=Curated
|PharmGKB Accession ID=PA165110200
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2853539
|overall_frequency_n=81
|overall_frequency_d=128
|overall_frequency=0.632812
|n_genomes=48
|n_genomes_annotated=0
|n_haplomes=72
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}
{{on chip | 23andMe v3}}